MedPath

The Effect of Ivabradine Treatment on Exercise Capacity in Patients with Chronic Rejection after Heart Transplantatio

Phase 1
Conditions
Cardiac allograft vasculopathy and elevated resting heart rate in heart transplant recipients
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
MedDRA version: 20.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849
Registration Number
EUCTR2016-004706-33-DK
Lead Sponsor
Finn Gustafsson
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
35
Inclusion Criteria

•Patients > 1 year post heart transplantation
•CAV verified by coronary angiography or IVUS
•Resting HR > 80 bpm
•Age > 18 years
•Signed informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 35
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Rejection (>H1R) < 3 months
•Severe renal failure (estimated GFR < 30 mL/min/1.73 m2)
•Inability or contraindication to perform a VO2max test
•Presence of any condition that might per se influence exercise performance
•Known contraindication for treatment with ivabradine
•Hypersensitivity to the active substance or to any of the excipients of either study drug

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath